Table of Contents

Global CXCR4 Antagonists Market Growth (Status and Outlook) 2019-2024

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global CXCR4 Antagonists Market Size 2014-2024
  • 2.1.2 CXCR4 Antagonists Market Size CAGR by Region
• 2.2 CXCR4 Antagonists Segment by Type
  • 2.2.1 BL-8040
  • 2.2.2 BL-8040
  • 2.2.3 Plerixafor (AMD3100)
  • 2.2.4 Balixafortide (POL6326)
  • 2.2.5 USL311
  • 2.2.6 Others
• 2.3 CXCR4 Antagonists Market Size by Type
  • 2.3.1 Global CXCR4 Antagonists Market Size Market Share by Type (2014-2019)
  • 2.3.2 Global CXCR4 Antagonists Market Size Growth Rate by Type (2014-2019)
• 2.4 CXCR4 Antagonists Segment by Application
  • 2.4.1 Cancer
  • 2.4.2 HIV
  • 2.4.3 Chronic Inflammatory Diseases
• 2.5 CXCR4 Antagonists Market Size by Application
  • 2.5.1 Global CXCR4 Antagonists Market Size Market Share by Application (2014-2019)
  • 2.5.2 Global CXCR4 Antagonists Market Size Growth Rate by Application (2014-2019)

3 Global CXCR4 Antagonists by Players

• 3.1 Global CXCR4 Antagonists Market Size Market Share by Players
  • 3.1.1 Global CXCR4 Antagonists Market Size by Players (2017-2019)
  • 3.1.2 Global CXCR4 Antagonists Market Size Market Share by Players (2017-2019)
• 3.2 Global CXCR4 Antagonists Key Players Head office and Products Offered
• 3.3 Market Concentration Rate Analysis
  • 3.3.1 Competition Landscape Analysis
  • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.4 New Products and Potential Entrants
• 3.5 Mergers & Acquisitions, Expansion

4 CXCR4 Antagonists by Regions

• 4.1 CXCR4 Antagonists Market Size by Regions
• 4.2 Americas CXCR4 Antagonists Market Size Growth
• 4.3 APAC CXCR4 Antagonists Market Size Growth
• 4.4 Europe CXCR4 Antagonists Market Size Growth
• 4.5 Middle East & Africa CXCR4 Antagonists Market Size Growth

5 Americas

• 5.1 Americas CXCR4 Antagonists Market Size by Countries
• 5.2 Americas CXCR4 Antagonists Market Size by Type
• 5.3 Americas CXCR4 Antagonists Market Size by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC CXCR4 Antagonists Market Size by Countries
• 6.2 APAC CXCR4 Antagonists Market Size by Type
• 6.3 APAC CXCR4 Antagonists Market Size by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe CXCR4 Antagonists by Countries
• 7.2 Europe CXCR4 Antagonists Market Size by Type
• 7.3 Europe CXCR4 Antagonists Market Size by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa CXCR4 Antagonists by Countries
• 8.2 Middle East & Africa CXCR4 Antagonists Market Size by Type
• 8.3 Middle East & Africa CXCR4 Antagonists Market Size by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Global CXCR4 Antagonists Market Forecast

• 10.1 Global CXCR4 Antagonists Market Size Forecast (2019-2024)
• 10.2 Global CXCR4 Antagonists Forecast by Regions
  • 10.2.1 Global CXCR4 Antagonists Forecast by Regions (2019-2024)
  • 10.2.2 Americas Market Forecast
  • 10.2.3 APAC Market Forecast
  • 10.2.4 Europe Market Forecast
  • 10.2.5 Middle East & Africa Market Forecast
• 10.3 Americas Forecast by Countries
  • 10.3.1 United States Market Forecast
  • 10.3.2 Canada Market Forecast
  • 10.3.3 Mexico Market Forecast
  • 10.3.4 Brazil Market Forecast
• 10.4 APAC Forecast by Countries
  • 10.4.1 China Market Forecast
  • 10.4.2 Japan Market Forecast
  • 10.4.3 Korea Market Forecast
  • 10.4.4 Southeast Asia Market Forecast
  • 10.4.5 India Market Forecast
  • 10.4.6 Australia Market Forecast
• 10.5 Europe Forecast by Countries
  • 10.5.1 Germany Market Forecast
  • 10.5.2 France Market Forecast
  • 10.5.3 UK Market Forecast
  • 10.5.4 Italy Market Forecast
  • 10.5.5 Russia Market Forecast
  • 10.5.6 Spain Market Forecast
• 10.6 Middle East & Africa Forecast by Countries
  • 10.6.1 Egypt Market Forecast
  • 10.6.2 South Africa Market Forecast
  • 10.6.3 Israel Market Forecast
  • 10.6.4 Turkey Market Forecast
  • 10.6.5 GCC Countries Market Forecast
• 10.7 Global CXCR4 Antagonists Forecast by Type
• 10.8 Global CXCR4 Antagonists Forecast by Application

11 Key Players Analysis

• 11.1 Eli Lilly
  • 11.1.1 Company Details
  • 11.1.2 CXCR4 Antagonists Product Offered
  • 11.1.3 Eli Lilly CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.1.4 Main Business Overview
  • 11.1.5 Eli Lilly News
• 11.2 Upsher-Smith Laboratories
  • 11.2.1 Company Details
  • 11.2.2 CXCR4 Antagonists Product Offered
  • 11.2.3 Upsher-Smith Laboratories CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.2.4 Main Business Overview
  • 11.2.5 Upsher-Smith Laboratories News
• 11.3 BioLineRx
  • 11.3.1 Company Details
  • 11.3.2 CXCR4 Antagonists Product Offered
  • 11.3.3 BioLineRx CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.3.4 Main Business Overview
  • 11.3.5 BioLineRx News
• 11.4 Sanofi
  • 11.4.1 Company Details
  • 11.4.2 CXCR4 Antagonists Product Offered
  • 11.4.3 Sanofi CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.4.4 Main Business Overview
  • 11.4.5 Sanofi News
• 11.5 Roche
  • 11.5.1 Company Details
  • 11.5.2 CXCR4 Antagonists Product Offered
  • 11.5.3 Roche CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.5.4 Main Business Overview
  • 11.5.5 Roche News
• 11.6 X4 Pharmaceuticals
  • 11.6.1 Company Details
  • 11.6.2 CXCR4 Antagonists Product Offered
  • 11.6.3 X4 Pharmaceuticals CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.6.4 Main Business Overview
  • 11.6.5 X4 Pharmaceuticals News
• 11.7 GlycoMimetics
  • 11.7.1 Company Details
  • 11.7.2 CXCR4 Antagonists Product Offered
  • 11.7.3 GlycoMimetics CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.7.4 Main Business Overview
  • 11.7.5 GlycoMimetics News
• 11.8 Merck
  • 11.8.1 Company Details
  • 11.8.2 CXCR4 Antagonists Product Offered
  • 11.8.3 Merck CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.8.4 Main Business Overview
  • 11.8.5 Merck News
• 11.9 Harmonic Pharma
  • 11.9.1 Company Details
  • 11.9.2 CXCR4 Antagonists Product Offered
  • 11.9.3 Harmonic Pharma CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.9.4 Main Business Overview
  • 11.9.5 Harmonic Pharma News
• 11.10 Biokine Therapeutics
  • 11.10.1 Company Details
  • 11.10.2 CXCR4 Antagonists Product Offered
  • 11.10.3 Biokine Therapeutics CXCR4 Antagonists Revenue, Gross Margin and Market Share (2017-2019)
  • 11.10.4 Main Business Overview
  • 11.10.5 Biokine Therapeutics News

12 Research Findings and Conclusion

According to this study, over the next five years the CXCR4 Antagonists market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in CXCR4 Antagonists business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of CXCR4 Antagonists market by product type, application, key companies and key regions.

This study considers the CXCR4 Antagonists value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Others

Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Cancer
HIV
Chronic Inflammatory Diseases

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Eli Lilly
Upsher-Smith Laboratories
BioLineRx
Sanofi
Roche
X4 Pharmaceuticals
GlycoMimetics
Merck
Harmonic Pharma
Biokine Therapeutics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global CXCR4 Antagonists market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of CXCR4 Antagonists market by identifying its various subsegments.
Focuses on the key global CXCR4 Antagonists players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the CXCR4 Antagonists with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of CXCR4 Antagonists submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.